E1 ReplicatedModerate confidencePEM not requiredRCTPeer-reviewedReviewed
Standard · 3 min
Immunologic and psychologic therapy for patients with chronic fatigue syndrome: a double-blind, placebo-controlled trial.
Lloyd, A R, Hickie, I, Brockman, A et al. · The American journal of medicine · 1993 · DOI
Quick Summary
This study tested whether two treatments—an immune-boosting extract and cognitive-behavioral therapy (a talk therapy focused on thoughts and behaviors)—could help people with ME/CFS. Ninety patients received either these treatments, a placebo, or combinations of both in a blinded trial. Neither treatment worked better than placebo, suggesting that the improvement some patients experienced may have been due to placebo effect or natural recovery rather than the specific treatments tested.
Why It Matters
This rigorous, high-quality trial addresses whether two plausible ME/CFS treatments—immunologic intervention and behavioral therapy—are actually effective, providing important evidence against their specific benefit. The findings help redirect research focus and prevent ineffective treatments from becoming standard practice, ultimately improving how ME/CFS treatment is approached.
Observed Findings
Both treatment and placebo groups showed improvement in global well-being, physical capacity, functional status, and mood over the study period.
No significant differences were found between dialyzable leukocyte extract-treated and placebo-treated patients.
No significant differences were found between CBT-treated and non-CBT-treated patients.
Combination therapy did not outperform single treatments or placebo.
Peripheral blood T-cell subsets and delayed-type hypersensitivity responses were measured but showed no differential treatment response.
Inferred Conclusions
Dialyzable leukocyte extract does not provide specific therapeutic benefit in CFS beyond placebo effect.
Cognitive-behavioral therapy does not provide specific therapeutic benefit in CFS beyond placebo effect.
Improvement observed in CFS patient cohorts may reflect nonspecific treatment effects and the natural history of the disease, including spontaneous remission.
Patients with CFS do not demonstrate a specific immunologic or psychologic abnormality that responds to targeted therapy in the way this trial was designed.
Remaining Questions
Why did all groups (treatment and placebo) show improvement, and what specific nonspecific factors (e.g., attention, therapeutic alliance, natural remission rate) drove this improvement?
What This Study Does Not Prove
This study does not prove that CBT or immune-modulating therapies are never helpful for any ME/CFS patients; it shows they were not superior to placebo in this particular trial population and timeframe. The negative findings do not explain the biological mechanisms of ME/CFS or rule out other potential treatments. The study also does not establish whether different patient subgroups, dosages, or treatment durations might show different responses.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.